These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 17699871)

  • 21. β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib.
    Huang C; Park CC; Hilsenbeck SG; Ward R; Rimawi MF; Wang YC; Shou J; Bissell MJ; Osborne CK; Schiff R
    Breast Cancer Res; 2011 Aug; 13(4):R84. PubMed ID: 21884573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
    Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
    Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.
    O'Brien NA; Browne BC; Chow L; Wang Y; Ginther C; Arboleda J; Duffy MJ; Crown J; O'Donovan N; Slamon DJ
    Mol Cancer Ther; 2010 Jun; 9(6):1489-502. PubMed ID: 20501798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.
    Kalous O; Conklin D; Desai AJ; O'Brien NA; Ginther C; Anderson L; Cohen DJ; Britten CD; Taylor I; Christensen JG; Slamon DJ; Finn RS
    Mol Cancer Ther; 2012 Sep; 11(9):1978-87. PubMed ID: 22761403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells.
    Kang JC; Poovassery JS; Bansal P; You S; Manjarres IM; Ober RJ; Ward ES
    MAbs; 2014; 6(2):340-53. PubMed ID: 24492289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity.
    Scaltriti M; Verma C; Guzman M; Jimenez J; Parra JL; Pedersen K; Smith DJ; Landolfi S; Ramon y Cajal S; Arribas J; Baselga J
    Oncogene; 2009 Feb; 28(6):803-14. PubMed ID: 19060928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.
    Arpino G; Gutierrez C; Weiss H; Rimawi M; Massarweh S; Bharwani L; De Placido S; Osborne CK; Schiff R
    J Natl Cancer Inst; 2007 May; 99(9):694-705. PubMed ID: 17470737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
    Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
    J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HB-EGF orchestrates the complex signals involved in triple-negative and trastuzumab-resistant breast cancer.
    Yotsumoto F; Oki E; Tokunaga E; Maehara Y; Kuroki M; Miyamoto S
    Int J Cancer; 2010 Dec; 127(11):2707-17. PubMed ID: 20499311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models.
    Wu Y; Zhang Y; Wang M; Li Q; Qu Z; Shi V; Kraft P; Kim S; Gao Y; Pak J; Youngster S; Horak ID; Greenberger LM
    Mol Cancer Ther; 2013 Apr; 12(4):427-37. PubMed ID: 23395887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines.
    Puig T; Aguilar H; Cufí S; Oliveras G; Turrado C; Ortega-Gutiérrez S; Benhamú B; López-Rodríguez ML; Urruticoechea A; Colomer R
    Breast Cancer Res; 2011; 13(6):R131. PubMed ID: 22177475
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members.
    Wheeler DL; Huang S; Kruser TJ; Nechrebecki MM; Armstrong EA; Benavente S; Gondi V; Hsu KT; Harari PM
    Oncogene; 2008 Jun; 27(28):3944-56. PubMed ID: 18297114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
    Konecny GE; Pegram MD; Venkatesan N; Finn R; Yang G; Rahmeh M; Untch M; Rusnak DW; Spehar G; Mullin RJ; Keith BR; Gilmer TM; Berger M; Podratz KC; Slamon DJ
    Cancer Res; 2006 Feb; 66(3):1630-9. PubMed ID: 16452222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).
    Oliveras-Ferraros C; Vazquez-Martin A; Martin-Castilló B; Pérez-Martínez MC; Cufí S; Del Barco S; Bernado L; Brunet J; López-Bonet E; Menendez JA
    Int J Oncol; 2010 Sep; 37(3):669-78. PubMed ID: 20664936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth.
    Vazquez-Martin A; Oliveras-Ferraros C; Cufí S; Del Barco S; Martin-Castillo B; Menendez JA
    J Cell Physiol; 2011 Jan; 226(1):52-7. PubMed ID: 20658522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas.
    Larbouret C; Robert B; Navarro-Teulon I; Thèzenas S; Ladjemi MZ; Morisseau S; Campigna E; Bibeau F; Mach JP; Pèlegrin A; Azria D
    Clin Cancer Res; 2007 Jun; 13(11):3356-62. PubMed ID: 17545543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [
    Chan C; Fonge H; Lam K; Reilly RM
    Nucl Med Biol; 2020; 80-81():37-44. PubMed ID: 31706737
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
    Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
    Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells.
    Fessler SP; Wotkowicz MT; Mahanta SK; Bamdad C
    Breast Cancer Res Treat; 2009 Nov; 118(1):113-24. PubMed ID: 19415485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.